$PFE Headlines 10 stocks for the U.S. economy’s revival

New Post Public Reply Private Reply Replies (0) Message Board

Dec 29, 2013 at 9:56 AM

$PFE Headlines

10 stocks for the U.S. economy’s revival in 2014 10:14 a.m. Dec. 27, 2013 - Diana Furchtgott-Roth
Not all pharmaceuticals are created equal 12:39 p.m. Dec. 26, 2013 - The Trading Deck
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - blogs.marketwatch.com
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Value investing for retirement portfolios 6:01 a.m. Dec. 7, 2013 - Robert Powell
Auxilium shares soar after FDA approves drug for additional use 3:53 p.m. Dec. 6, 2013 - blogs.marketwatch.com
A tale of two drug companies 4:13 p.m. Dec. 5, 2013 - Mark Hulbert
3 low-risk stocks for market skeptics 6:15 a.m. Dec. 5, 2013 - Jeff Reeves
DuPont, Pfizer are top decliners in Dow index 4:01 p.m. Dec. 3, 2013 - Polya Lesova
Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Pfizer's Rapamune doesn't meet primary endpoint 8:51 a.m. Nov. 8, 2013 - MarketWatch.com
Is this March 2000 all over again? 3:07 p.m. Nov. 7, 2013 - Mark Hulbert
Newscast: The Dow and S&P 500 set new record highs 6:31 p.m. Oct. 29, 2013 - MarketWatch
Energy stocks gain; BP shares rally on earnings 5:12 p.m. Oct. 29, 2013 - Claudia Assis
S&P 500, Dow industrials close at record highs 4:41 p.m. Oct. 29, 2013 - Victor Reklaitis
Newscast: Wall Street heads higher and sets record 4:33 p.m. Oct. 29, 2013 - MarketWatch

Hold the Sizzle - Michael Price's Low P/E Stocks in Review 8:30 p.m. Dec. 28, 2013 - GuruFocus.com
Merck Plans Radical Overhaul of Drug R&D Unit 5:20 p.m. Dec. 27, 2013 - WSJ.com
Three S&P 500 and Dow Industrial Companies Report Dividend Growth and Buyback Extensions 5:20 p.m. Dec. 27, 2013 - GuruFocus.com
Is There Still Room To Profit With Halozyme? 12:52 p.m. Dec. 27, 2013 - Seeking Alpha
Best Stocks for 2014 12:39 a.m. Dec. 27, 2013 - Barrons.com
Pfizer Becomes #22 Most Shorted Dow Stock, Replacing Goldman Sachs Group 11:17 a.m. Dec. 26, 2013 - TheStreet.com
A Strong Sign for 2014 – Capital Spending vs Buybacks 4:00 a.m. Dec. 26, 2013 - InvestorPlace.com
Companies Binge on Share Buybacks 9:31 p.m. Dec. 25, 2013 - WSJ.com
Dividends: Big Dogs, Small Dogs And Spy Dogs 4:11 a.m. Dec. 25, 2013 - Seeking Alpha
Pipeline Progress at Athersys - Analyst Blog 5:20 p.m. Dec. 24, 2013 - Zacks.com
Update on Glaxo's HIV Drugs - Analyst Blog 4:30 p.m. Dec. 24, 2013 - Zacks.com
AT&T and Pfizer Top GuruFocus Dividend Growers of the Week 11:28 a.m. Dec. 24, 2013 - GuruFocus.com
Where Will GlaxoSmithKline Go Next? 10:50 a.m. Dec. 24, 2013 - Wall St. Cheat Sheet
Dow Dogs Drink To A Dominant 2013. Will They Toast A Triumphant 2014, Too? 10:38 a.m. Dec. 24, 2013 - Seeking Alpha
Capital Spending vs. Buybacks - Ahead of Wall Street 9:59 a.m. Dec. 24, 2013 - Zacks.com
Genetic Technologies updates patent program, grants license 8:19 a.m. Dec. 24, 2013 - Seeking Alpha
Big Pharma Stocks: Year in Review 6:00 a.m. Dec. 24, 2013 - TheStreet.com
Dow Today: Pfizer (PFE) Higher 2:00 p.m. Dec. 23, 2013 - TheStreet.com
21 Stocks Giving the Gift of Dividend Growth 11:23 a.m. Dec. 23, 2013 - GuruFocus.com
Flush Coffers, Fat Payouts 2:34 a.m. Dec. 21, 2013 - Barrons.com

Regulatory Submissions, New Clinical Trials, Results Scheduled, and Conference Calls - Research Report on Pfizer, Novartis, Teva, Universal Health Services, and BD 8:00 a.m. Dec. 24, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Patent Settlements, Stock Price Movements, and Financial Guidance - Research Report on Pfizer, Tenet, Rockwell Medical, Magellan Health Services, and HealthSouth 8:00 a.m. Dec. 20, 2013 - PR Newswire
FDA Accepts For Review ELIQUIS(R) (apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE 5:01 p.m. Dec. 19, 2013 - BusinessWire
Athersys Confirms Completion of Patient Enrollment of Pfizer's Phase II Study of MultiStem(R) Cell Therapy for Ulcerative Colitis 7:00 a.m. Dec. 19, 2013 - GlobeNewswire
Surgical Scar Market Is Ripe for Innovation 11:15 a.m. Dec. 18, 2013 - ACCESSWIRE
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept 8:00 a.m. Dec. 18, 2013 - PR Newswire
Teva Settles Viagra(R) Patent Litigation with Pfizer 4:35 p.m. Dec. 17, 2013 - BusinessWire
Pfizer Settles Viagra(R) Patent Litigation With Teva 11:55 a.m. Dec. 17, 2013 - BusinessWire
Pfizer Invites Public To View And Listen To Webcast Of January 28 Conference Call With Analysts 10:00 a.m. Dec. 17, 2013 - BusinessWire
Pfizer Names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business 9:00 a.m. Dec. 17, 2013 - BusinessWire
Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development 8:01 a.m. Dec. 17, 2013 - Marketwire
Pfizer Declares First-Quarter 2014 Dividend 11:20 a.m. Dec. 16, 2013 - BusinessWire
InvestorsObserver releases comments on Pfizer, Oracle, FedEx, Jabil Circuit, and Trulia 9:31 a.m. Dec. 16, 2013 - PR Newswire
Siemens Enters Into Master Agreement With Pfizer for Companion Diagnostics 9:26 a.m. Dec. 16, 2013 - BusinessWire
Critical Alerts For Pfizer, Halliburton, Joy Global, Anadarko Petroleum, and Hewlett Packard Released By InvestorsObserver 9:31 a.m. Dec. 12, 2013 - PR Newswire
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant 8:59 a.m. Dec. 11, 2013 - BusinessWire
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant 6:00 a.m. Dec. 11, 2013 - BusinessWire
Pharma Industry Morning Assessment: Pfizer, Merck & Co., AbbVie, and Zogenix 12:19 p.m. Dec. 10, 2013 - PR Newswire
New Clinical Data Access Policy, Portfolio Expansions, Positive Top Line Results and Stock Price Movements - Research Report on Pfizer, Amgen, Puma Biotechnology, Abbott Laboratories, and Agilent 8:00 a.m. Dec. 10, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...